Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

European Journal of Haematology

Volumn 92, Issue 5, 2014, Pages 413-420

  Koskenvesa, Perttu ^a   Kreutzman, Anna ^a   Rohon, Peter ^a,b   Pihlman, Markus ^a   Vakkila, Emmi ^a   Räsänen, Anu ^c   Vapaatalo, Mirja ^a   Remes, Kari ^d   Lundán, Tuija ^a,d   Hjorth Hansen, Henrik ^e   Vakkila, Jukka ^a   Simonsson, Bengt ^f   Mustjoki, Satu ^a   Porkka, Kimmo ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c KYMENLAAKSO CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic myeloid leukemia; Immune system; Interferon; Therapy discontinuation; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; IMATINIB; IMMUNOLOGIC FACTOR; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RECOMBINANT PROTEIN; TUMOR MARKER;

DRUG ADMINISTRATION; DRUG MONITORING; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PYRIMIDINES; RECOMBINANT PROTEINS; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898800461     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12258     Document Type: Article

References (21)

1. Mahon FX, Delbrel X, Cony-Makhoul P, Faberes C, Boiron JM, Barthe C, Bilhou-Nabera C, Pigneux A, Marit G, Reiffers J. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002;20:214-20.
2. Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011;118:3228-35.
3. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-21.
4. Burchert A, Muller MC, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010;28:1429-35.
5. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35.
6. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515-22.
7. Legros L, Rousselot P, Giraudier S, Tulliez M, Huguet F, Nicolini FE, Mahon FX. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood 2012;120:1959-60.
8. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
9. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010;85:387-98.
10. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010;116:772-82.
11. Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011;25:1587-97.
12. Ilander M, Koskenvesa P, Hernesniemi S, Lion T, Porkka K, Mustjoki S. Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy. Leuk Lymphoma 2013 [Epub ahead of print].
13. Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Shin S, Kim JA, Kim HS, Cho EH, Kwak JY. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 2012;36:689-93.
14. Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 2013; 49: 3242-6.
15. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24:1719-24.
16. Ohyashiki K, Katagiri S, Tauchi T, Ohyashiki JH, Maeda Y, Matsumura I, Kyo T. Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol 2012;157:254-6.
17. Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, Inokuchi K, Ohyashiki JH, Ohyashiki K. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci 2013;104:1146-53.
18. Kreutzman A, Rohon P, Faber E, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011;6:e23022.
19. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003;102:2892-900.
20. Yong AS, Keyvanfar K, Hensel N, et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009;113:875-82.
21. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096-102.